NEWS

Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News
Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II …
Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drugGeekWire
Juno Therapeutics’ Q4 Financial Results Overshadowed by Pipeline SetbackMadison.com
Juno ends flagship drug trial after deaths and FDA suspensionsPuget Sound Business Journal (Seattle)
KFGO –OncLive
all 30 news articles »

‘Superbugs’ could be killed with ‘genetic chainsaw’ version of gene editor CRISPR
Genetic Literacy Project
When folks talk about the gene-editing tool CRISPR, they’re usually talking about CRISPR-Cas9, a combination of DNA and enzymes that together act like scissors to cut and paste genes. CRISPR-Cas9 has already been hailed a potential game changer in …

and more »

Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News (press release)
Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II …
Juno ditches lead CAR–T program following patient deathsFierceBiotech
After Trial Deaths, Juno Pivots and Scraps Lead CAR–T TherapyXconomy
Months after another lethal setback, Juno finally opts to kill lead CAR–TEndpoints News
OncLive –BioPharma Dive –Investopedia
all 59 news articles »

D-backs’ De La Rosa counting on stem–cell therapy to avoid second Tommy John
Arizona Sports (registration) (blog)
Rubby De La Rosa had already undergone Tommy John surgery. So when his right elbow became an issue again, he had a tough decision to make. He could have the surgery again and risk that it might not be as effective the second time around. Or he could …

and more »

D-backs’ De La Rosa counting on stem–cell therapy to avoid second Tommy John
Arizona Sports (registration) (blog)
Rubby De La Rosa had already undergone Tommy John surgery. So when his right elbow became an issue again, he had a tough decision to make. He could have the surgery again and risk that it might not be as effective the second time around. Or he could …

and more »

Stem cell research gives new hope for treating heart failure, heart disease, diabetes and Parkinson’s
dailytelegraph.com.au
PhD student Richard Tan, who led the research project, said stem cells have the power to treat heart failure and heart disease, diabetes, Parkinson’s and cerebral palsy, but until now injected cells were failing to graft onto damaged tissue. The team …
Here’s the Story on US Stem Cell Inc (OTCMKTS:USRM)The Oracle Dispatch
Evolution of new destinations in the development of Global Stem Cell Therapy Market to grow at a CAGR of 36.52 …Medgadget (blog)
ISSCR 2017Drug Target Review
QWTJ LIVE One Stop
all 8 news articles »

Stem cell research gives new hope for treating heart failure, heart disease, diabetes and Parkinson’s
dailytelegraph.com.au
PhD student Richard Tan, who led the research project, said stem cells have the power to treat heart failure and heart disease, diabetes, Parkinson’s and cerebral palsy, but until now injected cells were failing to graft onto damaged tissue. The team …
Here’s the Story on US Stem Cell Inc (OTCMKTS:USRM)The Oracle Dispatch
Evolution of new destinations in the development of Global Stem Cell Therapy Market to grow at a CAGR of 36.52 …Medgadget (blog)
ISSCR 2017Drug Target Review
QWTJ LIVE One Stop
all 8 news articles »